Formation Bio

Formation Bio is a tech-driven, AI-native pharmaceutical company revolutionizing drug development. By leveraging a proprietary technology platform, they expedite the development of treatments, aiming to meet critical unmet patient needs efficiently without compromising quality or safety. They acquire clinical-stage drugs from various sources and enhance their development process to achieve faster inflection points than industry norms. Their multidisciplinary team combines extensive expertise in drug selection, development, and technology, having collectively worked on over 45 approved drugs, ensuring a robust and innovative approach to bringing new treatments to patients.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Series D26 Jun, 2024
***
***
***
Series C30 Sep, 2021
***
***
***
Series B1 Oct, 2018
***
***
***
Series A28 Sep, 2017
***
***
***
Seed1 Jun, 2016
***
***
***

*** - To view the data, please log into your account or create a new one.

Company valuation calculator

To calculate, specify one of the parameters

News related to Formation Bio16

Filter by
Sort by
Formation Bio
Oct 29, 2026 •Show on chart

Formation Bio Announces $600 Million Debut Fund to Expand Drug ...

PRNewswire/ -- Formation Bio, an AI-native pharmaceutical company, today announced the Formation Bio Drug Development Accelerator Fund (the "Fund"), ...

https://www.prnewswire.com/news-releases/formation-bio-announces-600-million-debut-fund-to-expand-drug-development-capacity-302921852.html
Formation Bio
Sep 9, 2026 •Show on chart

Formation Bio's AI-ready repository of knowledge - Fast Company

Formation Bio used AI to make its vast trove of data more readily available to employees, landing the company at No. 7 on Best Workplaces for Innovators ...

https://www.fastcompany.com/91591991/formation-bio-best-workplaces-for-innovators-2026
Formation Bio
Jul 23, 2026 •Show on chart

Former Biogen Executive to Lead Research at Formation Bio

Formation Bio said it has appointed former Biogen Inc. research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech ...

https://www.bloomberg.com/news/articles/2026-07-22/former-biogen-executive-to-lead-research-at-formation-bio
Formation Bio
Jul 23, 2026 •Show on chart

Formation Bio Appoints Michael Ehlers as Chief Scientific Officer ...

PRNewswire/ -- Formation Bio, an AI-native pharma company, today announced the appointment of Michael D. Ehlers, MD, PhD, as Chief Scientific Officer (CSO)....

https://www.prnewswire.com/news-releases/formation-bio-appoints-michael-ehlers-as-chief-scientific-officer-and-head-of-rd-302831565.html
Formation Bio
Jun 11, 2026 •Show on chart

Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant ...

Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 ...

https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-partner-formation-bio-doses-first-participant-in-phase-1-trial-of-blkr201-originally-designated-as-lnk01006-a-cns-penetrant-tyk2-inhibitor-302795367.html
Show more (11)

Investors3

Andreessen HorowitzAndreessen Horowitz
Sequoia CapitalSequoia Capital
Thrive CapitalThrive Capital